Evolution of Lipid Therapy 4/14
| Start Date |
Monday, April 14, 2008 |
| End Date |
Monday, April 14, 2008 |
| Description |
Most patients require multiple medications to achieve optimal CV risk reduction. Many therapeutic agents have been proven effective when used alone, but combination therapy has become the new “gold standard” for CV risk reduction. This program provides practical advice on enhancing adherence through fixed-dose combinations and ongoing patient education and offers insights into the continuous evolution of dyslipidemia therapy. |
| Phone |
1 888-200-3176 |
| Fax |
1 888-200-4046 |
| E-mail |
info@cmhfound.org |
| Website |
http://www.cmhreg.org |
| Format |
Teleconference |
| Credit Hours |
1 |
| Price |
FREE |
| Specialties |
Cardiology, Family Practice/Medicine, Internal Medicine, Physician's Assistant, Nurse Practitioner, Nurse |
| Topic(s) |
Cardiovascular and metabolic health |
| Objectives |
After completing this activity, the participant should be better able to: • Describe how the concept of “residual risk” applies to patients with mixed dyslipidemia; that most patients require therapy that targets more than one lipid parameter • Explain how HDL-C is an independent risk factor for CHD • Describe important barriers to optimal risk reduction with currently available treatments • Describe the benefits of fixed-dose combination therapy for mixed dyslipidemia • Summarize how multiple lipid risk factors contribute to a patient’s total risk profile • Outline how fixed-dose combinations in lipid therapy can provide enhanced patient benefit • List strategies to treat elevated LDL-C levels and low HDL-C levels • Describe how to enhance patient care for those requiring niacin therapy with ongoing education, coaching, and focused discussions about tolerability and adherence • Outline an appropriate treatment and ongoing education strategy for a patient with mixed dyslipidemia. |
|